1090 Horsham Road
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
1628 articles with Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report , demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content. Th
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine
Teva Pharmaceutical Industries Ltd. presented a wide range of important new data on AJOVY® and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology.
Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress
Teva Pharmaceutical Industries Ltd. announced that new data on AJOVY® and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology, being held virtually from 23-26 May 2020.
China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
Teva Pharmaceutical Industries Ltd., announced that the China National Medical Products Administration has approved AUSTEDO® for the treatment of chorea associated with Huntington's disease and Tardive Dyskinesia in adults, after a priority review.
Revenues of $4.4 billion GAAP diluted EPS of $0.06 Non-GAAP diluted EPS of $0.76 Free cash flow of $551 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan® (rituximab) Available in the United States for This Indication
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA ® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan ® (rituximab) Available in the United States for This Indication TRUXIMA is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Included in Neurology
New Data For Teva AJOVY ® (fremanezumab-vfrm) Injection and AUSTEDO ® (deutetrabenazine) Tablets Included in Neurology 23 abstracts appeared in the 2020 American Academy of Neurology (AAN) Science Highlights Supplement
Teva Canada Announces the Launch of AJOVY™ For the Preventive Treatment of Migraine in Adults Who Have at Least Four Migraine Days Per Month
AJOVY™ is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults
Shares of Eagle Pharmaceuticals and Teva Pharmaceuticals are climbing following a favorable ruling in U.S. District Court that protects the patent for cancer drug Bendeka from generic competition through 2031.
Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. announced that on April 27, 2020, the U.S. District Court for the District of Delaware has issued a patent decision in favor of Eagle and Teva for BENDEKA®, a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride..
Teva Announces U.S. Launch of Autoinjector for AJOVY ® (fremanezumab-vfrm) Injection
Teva to Host Conference Call to Discuss First Quarter 2020 Financial Results at 8 a.m. ET on May 7, 2020
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter financial results on Thursday, May 7, 2020 at 7:00 a.m. ET.
Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide
Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA ® (trastuzumab-pkrb) for Injection
Teva Pharmaceutical Europe BV an affiliate of Teva Pharmaceutical Industries Ltd. announced that the National Institute for Health and Care Excellence has recommended AJOVY in its Final Appraisal Document for the prevention of migraine in adults with chronic migraine.
Amalia Adler-Waxman, vice president of Social Impact and Responsibility at Teva, told BioSpace that the company believes everyone should have access to essential medications, regardless of their geographic location.
2/24/2020Mid-February had a solid number of clinical trial announcements. Here’s a look.
Teva's deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint
Teva Pharmaceutical Industries Ltd. announced the Phase 2/3 ARTISTS 1 and Phase 3 ARTISTS 2 trials designed to evaluate deutetrabenazine compared to placebo for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome failed to meet the primary endpoint of reduction in motor and phonic tics as assessed by the Total Tic Score of the Yale Global Tic Severity Scale.